Palatin Technologies Aktie

Kaufen

Verkaufen

0,0800 EUR -0,0022 EUR -2,68 %

28.05.2025

STU

1,10 USD -1,11 USD -50,23 %

07.02.2025

LSE

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Bei einem anderen Broker handeln Smartphone

Marktkap.4,21 Mio. EUR

Div. Rendite0,00%

WKNA3DTUW

ISINUS6960775020

SymbolPTNT

Palatin Technologies Aktien News

Sortieren:Datum Meistgelesen

28.02.24PR NewswirePalatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

15.02.24PR NewswirePalatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

09.02.24PR NewswirePalatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024

05.02.24PR NewswirePalatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

08.01.24PR NewswirePalatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024

20.12.23PR NewswirePalatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million

18.12.23PR NewswirePalatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American

14.11.23PR NewswirePalatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

09.11.23PR NewswirePalatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023

19.10.23PR NewswirePalatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue Results

18.10.23PR NewswirePalatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients

16.10.23PR NewswirePalatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis Treatment

13.10.23PR NewswirePalatin Receives Notice of Non-Compliance from NYSE American

28.09.23PR NewswirePalatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate Update

22.09.23PR NewswirePalatin to Report Fourth Quarter and Fiscal Year End 2023 Results; Teleconference and Webcast to be held on September 28, 2023

07.09.23PR NewswirePalatin to Present at the H.C. Wainwright 25th Annual Global Investment Conference

07.09.23PR NewswirePalatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye Disease

10.08.23PR NewswirePalatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment

08.08.23PR NewswirePalatin's Vyleesi® Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study

04.08.23PR NewswirePalatin to Participate in Canaccord Genuity's 43rd Annual Growth Conference

11.07.23PR NewswirePalatin Announces Preliminary Fourth Quarter Fiscal 2023 Vyleesi® Product Revenue Results

30.05.23PR NewswirePalatin Presents Preclinical Diabetic Nephropathy Data at the International Podocyte Conference

16.05.23PR NewswirePalatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

11.05.23PR NewswirePalatin to Report Third Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on May 16, 2023

09.05.23PR NewswirePalatin Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference

08.05.23PR NewswirePalatin Invites Investors to Listen to Replay of the PL9643 Dry Eye Disease Key Opinion Leader Webinar

01.05.23PR NewswirePalatin Technologies to Host Key Opinion Leader Webinar

27.04.23PR NewswirePalatin Presents Initial Dry Eye Disease Phase 3 Clinical Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference

25.04.23PR NewswirePalatin Presents Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference Regarding a Potential Treatment for Glaucoma

19.04.23PR NewswirePalatin Announces Preliminary Third Quarter Fiscal 2023 Vyleesi® Product Revenue Results

18.04.23PR NewswirePre-Clinical Data of Palatin's Melanocortin Agonist Demonstrating Therapeutic Effects in Diabetic Retinopathy and Uveitis Published in the International Journal of Molecular Sciences

02.03.23PR NewswireFrontiers in Immunology Publishes Pre-Clinical Study of Palatin's Oral Formulation of PL8177 Demonstrating Therapeutic Effects in Inflammatory Bowel Disease

15.02.23PR NewswirePalatin Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

10.02.23PR NewswirePalatin to Report Second Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on February 15, 2023

19.01.23PR NewswirePalatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease

18.01.23PR NewswirePalatin Receives $4.7 Million of Non-Dilutive Funding

10.01.23PR NewswireFrontiers in Immunology Publishes Pre-Clinical Study of Palatin's PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions

05.01.23PR NewswirePalatin Announces Preliminary Second Quarter Fiscal 2023 Vyleesi® Product Sales Results

14.11.22PR NewswirePalatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

09.11.22PR NewswirePalatin to Report First Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on November 14, 2022

Palatin Technologies News

Palatin Technologies News: auf dieser Seite finden Sie alle Palatin Technologies News und Nachrichten zur Palatin Technologies Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Palatin Technologies News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Palatin Technologies News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.